Effect of Topical Application of Antimicrobial Peptide PL ‐5 (Peceleganan) Spray on Mild to Moderate Infection of Diabetic Foot Ulcers: A Multicenter, Randomized, Double‐Blinded, Placebo‐Controlled Clinical Trial
Authors:
Open Access
- 27 July 2026
- journal article
- research article
- Published by Wiley in Journal of Diabetes
- Vol. 18 (7) , e70255
Abstract
Aims: To evaluate the clinical efficacy and safety of topical antimicrobial peptide PL‐5 (Peceleganan) spray combined with standard debridement in the treatment of mildly to moderately infected diabetic foot ulcers (DFUs). Materials and Methods: This multicenter, randomized, double‐blind, placebo‐controlled trial was conducted in four tertiary hospitals. Eligible patients were randomized to PL‐5 spray or placebo, both receiving standardized debridement. The primary endpoint was clinical response rate at 1 day after end of treatment (EOT1). Results: Baseline characteristics were balanced between groups. The clinical response rate at EOT1 was significantly higher in the PL‐5 group than in the placebo group ( p < 0.05). The clearance rate of drug‐resistant bacteria at EOT1 was 71.43% in the PL‐5 group versus 50% in the control group ( p < 0.05). No significant differences were observed in overall microbiological eradication rates at EOT1 (57.89% vs. 33.33%) or EOT7 (64.71% vs. 40.00%) (both p > 0.05). Adverse event rates were 24.24% in the PL‐5 group and 33.33% in the placebo group ( p > 0.05), with no serious drug‐related adverse events. PL‐5 showed a significant improvement in clinical effective rate, but overall microbiological eradication was not significantly different between groups. However, in the subset of patients with drug‐resistant bacteria, PL‐5 demonstrated a significantly higher clearance rate, suggesting potential for treatment of resistant infections. Conclusions: Topical PL‐5 spray improves clinical outcomes in mild‐to‐moderate infected diabetic foot ulcers and achieves superior pathogen clearance among drug‐resistant infection subgroups. It represents a promising low‐resistance topical option for managing mild to moderate DFU infections. Trial Registration: Chinese Clinical Trial Registry Identifier: ChiCTR2300068632Keywords
This publication has 27 references indexed in Scilit:
- Interventions in the management of diabetes‐related foot infections: A systematic reviewDiabetes/Metabolism Research and Reviews, 2023
- IWGDF/IDSA guidelines on the diagnosis and treatment of diabetes‐related foot infections (IWGDF/IDSA 2023)Diabetes/Metabolism Research and Reviews, 2023
- The impact of the length of total and intravenous systemic antibiotic therapy for the remission of diabetic foot infectionsInternational Journal of Infectious Diseases, 2022
- Interventions in the management of infection in the foot in diabetes: a systematic reviewDiabetes/Metabolism Research and Reviews, 2015
- Self-Reported Quality of Life and Diabetic Foot InfectionsThe Journal of Foot and Ankle Surgery, 2014
- Functional synergy of α-helical antimicrobial peptides and traditional antibiotics against Gram-negative and Gram-positive bacteria in vitro and in vivoEuropean Journal of Clinical Microbiology & Infectious Diseases, 2014
- Validation of the Infectious Diseases Society of America's Diabetic Foot Infection Classification SystemClinical Infectious Diseases, 2007
- Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trialThe Lancet, 2005
- Antimicrobial Peptides in Health and DiseaseNew England Journal of Medicine, 2002
- Antimicrobial peptides of multicellular organismsNature, 2002